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Overexpression of proto-oncogene FBI-1 activates
membrane type 1-matrix metalloproteinase in
association with adverse outcome in ovarian
cancers
LiLi Jiang1,3, Michelle KY Siu1, Oscar GW Wong1, Kar Fai Tam2, Eric W-F Lam4, Hextan YS Ngan2, Xiao-Feng Le5,
Esther SY Wong1, Hoi Yan Chan1, Annie NY Cheung1*
Abstract
Background: FBI-1 (factor that binds to the inducer of short transcripts of human immunodeficiency virus-1) is a
member of the POK (POZ and Kruppel) family of transcription factors and play important roles in cellular
differentiation and oncogenesis. Recent evidence suggests that FBI-1 is expressed at high levels in a subset of
human lymphomas and some epithelial solid tumors. However, the function of FBI-1 in human ovarian cancers
remains elusive.
Results: In this study, we investigated the role of FBI-1 in human ovarian cancers, in particularly, its function in
cancer cell invasion via modulating membrane type 1-matrix metalloproteinase (MT1-MMP). Significantly higher
FBI-1 protein and mRNA expression levels were demonstrated in ovarian cancers samples and cell lines compared
with borderline tumors and benign cystadenomas. Increased FBI-1 mRNA expression was correlated significantly
with gene amplification (P = 0.037). Moreover, higher FBI-1 expression was found in metastatic foci (P = 0.036) and
malignant ascites (P = 0.021), and was significantly associated with advanced stage (P = 0.012), shorter overall
survival (P = 0.032) and disease-free survival (P = 0.016). In vitro, overexpressed FBI-1 significantly enhanced cell
migration and invasion both in OVCA 420 and SKOV-3 ovarian carcinoma cells, irrespective of p53 status,
accompanied with elevated expression of MT1-MMP, but not MMP-2 or TIMP-2. Moreover, knockdown of MT1-
MMP abolished FBI-1-mediated cell migration and invasion. Conversely, stable knockdown of FBI-1 remarkably
reduced the motility of these cells with decreased expression of MT1-MMP. Promoter assay and chromatin
immunoprecipitation study indicated that FBI-1 could directly interact with the promoter spanning ~600bp of the
5’-flanking sequence of MT1-MMP and enhanced its expression in a dose-dependent manner. Furthermore, stable
knockdown and ectopic expression of FBI-1 decreased and increased cell proliferation respectively in OVCA 420,
but not in the p53 null SKOV-3 cells.
Conclusions: Our results suggested an important role of FBI-1 in ovarian cancer cell proliferation, cell mobility, and
invasiveness, and that FBI-1 can be a potential target of chemotherapy.
Background
Ovarian cancer is the leading cause of death among
gynecologic malignancies worldwide, and the survival
rates remain disappointing for patients suffering
from advanced cancers [1,2]. Development of cancer
metastasis is the major cause that kills patients with
ovarian cancer. However, the molecular mechanisms
contributing to its aggressiveness are still not fully
understood.
In the past decade, it has been established that
the matrix metalloproteinases (MMPs), including
Membrane-type-1 MMP (MT1-MMP or MMP14) and
MMP-2, play a critical role in degrading the basement
membrane and the extracellular matrix (ECM),
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resulting in tumor cell dissemination and outgrowth of
secondary cancers [3,4]. MT1-MMP not only directly
cleaves ECM components, but also functions as the
main activator of MMP-2 [5,6]. Conversely, tissue inhi-
bitor of metalloproteinase-2 (TIMP-2) inhibits MMP-2
after binding with its hemopexin domain [7,8]. As in
other solid cancers, MT1-MMP has been reported to
be widely expressed in ovarian cancers and related
malignant ascites of all histological types, but not in
normal ovarian epithelium or benign tumors [9-12].
Despite the central role of MT1-MMP in these cancer
metastases, little is known about its transcriptional reg-
ulators [13].
FBI-1 (also known as POKEMON, LRF in mouse, or
OCZF in rat), which was originally identified as a factor
that binds to the inducer of short transcripts (IST) ele-
ment of human HIV-1 genome [14], is a member of the
POK (POZ and krǔppel) family of transcription factor.
Recent reports revealed the participation of FBI-1 in
NF-B activation [15], adipogenesis [16], lymphocyte
differentiation [17], and oncogenesis [18-21]. Emerging
studies have shown that FBI-1 is strongly expressed in
diffuse large B-cell lymphoma, follicular lymphoma,
breast, lung, colon, prostate and bladder carcinomas
[18,22]. However, its role in ovarian tumors has not
been reported.
In the current study, we have illustrated a novel
mechanism that may account for the aggressiveness and
poor prognosis of human ovarian cancer. We showed
that FBI-1 interacted and activated MT1-MMP,
increased cell motility and invasion of ovarian cancer.
FBI-1 is significantly up-regulated in advanced stages of
ovarian cancer and associated with overall and disease
free survival of patients with ovarian tumors.
Results
Overexpression of FBI-1 protein in ovarian tumors and
cancer cell lines
The differential expression of FBI-1 in the various cate-
gories of ovarian tumors was shown in Figure 1A, and
its association with clinical-pathological parameters was
summarized in Table 1. All 10 benign cystadenomas (3
serous and 7 mucinous) were completely negative for
FBI-1 staining, while 15 out of 19 (78.9%) borderline
Figure 1 FBI-1 was overexpressed in ovarian tumors and correlated with prognosis of patients. A, Representative images of FBI-1
immunoreactivity in different ovarian tumor subtypes and malignant ascites (20×) (bottom right; 200×). B, mRNA expression (upper left panel)
and gene amplification status (upper right panel) of FBI-1 in clinical samples and the correlation of gene amplification patterns with mRNA
expression (lower panel). C, High expression of FBI-1 was associated with poor overall and disease-free survival.
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tumors (7 serous and 12 mucinous) showed weak and
focal immunoreactivity (score ≤9). Among the 111 ovar-
ian cancers, 82 (73.8%) cases displayed obvious overex-
pression of FBI-1 at a high level (score ≥12) both in the
cytoplasm and nuclei. Significant higher expression of
FBI-1 was found in borderline tumors (P < 0.001) and
cancers (P < 0.001) when compared with benign coun-
terparts. Expression of FBI-1 in cancers was also signifi-
cantly higher than that in borderline tumors (P <
0.001). However, there was no significant difference
among the four major histological types of ovarian
cancers (Table 1).
Western blot analysis showed that FBI-1 expression
was up-regulated in 11 out of the 13 (84.6%) ovarian
cancer cell lines (OVCAR3, OC316, DOV13, ES2,
OVCA 420, SKOV-3, TOV21G, TOV112 D, SW626,
2780 S, and 2780CP) when compared with two nontu-
morigenic immortalized human ovarian surface epithe-
lial cell (HOSE) lines (Figure 2A).
Gene amplification contributes to the overexpression of
FBI-1 mRNA
In a cohort of 36 pairs of clinical frozen samples, the
mRNA level of FBI-1 was found to be significantly up-
regulated in ovarian cancers when compared with corre-
sponding non-tumor counterparts (P = 0.005) by qPCR
(Figure 1B, left upper panel). Ten of the 13 (76.2%)
ovarian cancer cell lines also displayed up-regulation of
FBI-1 at mRNA level when compared with the average
of HOSE6-3 and HOSE11-12 (Figure 2B), although a
heterogeneous expression profile was observed.
To evaluate the mechanisms underlying the increase in
FBI-1 expression, genomic DNA copy number of FBI-1
was further evaluated in these 36 pairs of patient samples
using qPCR (Figure 1B, right upper panel). Remarkably,
31 out of 36 (86%) cancers displayed gene amplification
of FBI-1 when compared with the corresponding non-
tumor counterparts (Figure 1B, lower panel). Among the
31 amplified cases, 19 (61%) showed elevated mRNA
levels. In the 5 non-amplified cases, increased mRNA
expression of FBI-1 was only found in one case (20%).
Spearman’s rho test demonstrated that elevated RNA
transcription of FBI-1 was closely correlated with its gene
amplification (P = 0.037), suggesting that gene amplifica-
tion was an important mechanism leading to the overex-
pression of FBI-1 in ovarian cancers.
FBI-1 overexpression was significantly associated with
aggressive tumor behavior and poor outcome
In addition to primary cancer samples, 63 metastatic foci
in the lymph node, ligament, gut, and uterine serosa
derived from advanced ovarian cancers and 17 ascitic sam-
ples were also used for evaluating FBI-1 protein expression
by immunohistochemistry. Significant up-regulation of
Table 1 Association analysis between FBI-1 expression and the clinicopathological features of ovarian cancers
Case assessed Score
(mean ± SE)
p-value
Diagnostic categories Benign 10 0 0.000a
Borderline 19 7.83 ± 0.92 0.000a, 0.000b
Primary cancer 111 12.31 ± 0.37 0.000a
Metastatic foci 63 13.47 ± 0.46 0.036c
Malignant ascites 17 14.11 ± 0.87 0.021c
Histological types of ovarian cancer Serous 43 12.53 ± 1.04 0.070d
Endometrioid 36 11.82 ± 0.66
Clear cell 23 12.76 ± 0.53
Mucinous 9 12.11 ± 1.17
Stage Stage I 42 11.30 ± 0.67 0.012e
Stage II-IV 69 13.38 ± 0.42
Grade Low (grade I) 32 12.22 ± 0.73 0.151f
High (grade II and III) 79 12.39 ± 0.44
Response to primary chemotherapy Sensitive 78 12.14 ± 0.45 0.246g
Resistant 18 13.22 ± 0.92
Survival months 0.53~188.57 (average: 44.7)
a p Value reflects the comparison of each category vs. benign tumor.
b p Value reflects the comparison of primary cancer vs. borderline.
c p Value reflects the comparison of metastatic foci or malignant ascites versus primary cancer.
d p Value reflects the comparison of clear cell carcinoma versus all the other histological types combined.
e p Value reflects the comparison of stage I versus stage II-IV.
f p Value reflects the comparison of low grade versus. high grade.
g p Value reflects the comparison of chemosensitive versus chemoresistant.
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FBI-1 expression was detected in metastatic foci (P =
0.036) and malignant ascites (P = 0.021) (Figure 1A), com-
pared with primary malignancies (Table 1). Moreover,
higher FBI-1 expression was also found to be closely asso-
ciated with advanced stage (stage II-IV) (P = 0.012)
(Table 1), poor overall survival (P = 0.032) and disease-
free survival (P = 0.016) (Figure 1C). Nevertheless, there
was no significant correlation between FBI-1 immunoreac-
tivity and histological grade (P = 0.151) or chemosensitiv-
ity (P = 0.246). Although increased FBI-1 significantly
correlated with survival as mentioned above, multivariable
analysis showed that expression of FBI-1 was not an inde-
pendent predictor of overall survival (95% CI = 0.971-
1.089, P = 0.344), or disease-free survival (95% CI = 0.896-
1.080, P = 0.729). Together, our findings indicated that
FBI-1 may affect the prognosis of patients with ovarian
cancer via its effect on cancer progression.
FBI-1 promoted cell migration and invasion of ovarian
cancer with up-regulation of MT1-MMP
To further assess the function of FBI-1 on aggressive
behavior of ovarian cancer cells, OVCA 420 (harboring
wild-type p53) and SKOV-3 (possessing a single nucleo-
tide deletion at point 267 at codon 90 of p53, which
blocks p53 expression [23]) cells were transiently trans-
fected with pEGFP-FBI-1, followed by performing cell
migration and invasion assays. Among the various ovar-
ian cancer cell lines, OVCA 420 and SKOV-3 showed
average levels of FBI-1 expression.
Up to 7 and 10-fold increase in cell migration were
observed in OVCA 420 and SKOV-3 cells (both P <
0.001) (Figure 3A, upper panel) after transfection of
pEGFP-FBI-1. About 3-fold increase in cell invasion was
also observed in OVCA 420 (P = 0.007) and SKOV-3 (P
= 0.023) cells (Figure 3A, lower panel). Next, the mRNA
and protein expressions of FBI-1, MT1-MMP, MMP-2
and TIMP-2 were investigated. qPCR analysis showed
that along with the induced FBI-1 mRNA expression,
MT1-MMP, but not MMP-2 or TIMP-2, mRNA expres-
sion was increased by 3 to 6 fold after transfection of
pEGFP-FBI-1 (Figure 3B, upper panel). Western blot
analyses using anti-FBI-1 antibody also showed ectopic
expression of exogenous GFP-tagged FBI-1 (106KDa)
while no change in endogenous FBI-1 (75KDa) was
Figure 2 FBI-1 expression was up-regulated in most of the ovarian cancer cell lines when compared with normal ovarian epithelial
cell lines HOSE6-3 and HOSE11-12. A, protein expression and B, mRNA level of FBI-1 as determined by western blot and qPCR respectively.
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found. An up-regulation of total and active form of
MT1-MMP protein in both OVCA 420 and SKOV-3
cells after transfection of pEGFP-FBI-1 was also demon-
strated (Figure 3B, lower panel). No significant change
in MMP-2 and TIMP-2 expression was observed (data
not shown).
To test whether MT1-MMP is involved in FBI-1-
mediated cell migration and invasion, OVCA 420 and
SKOV-3 cells were transiently transfected with pEGFP-
FBI-1 and siRNA of MT1-MMP. Transient knockdown of
MT1-MMP inhibited both basal and FBI-1-enhanced cell
migration and invasion (Figure 3C; all P values < 0.05).
To further substantiate the notion that FBI-1 con-
ferred to ovarian cancer cell motility and invasiveness,
OVCA 420 and SKOV-3 cells with stably knockdown
FBI-1 were established and subjected to transwell
assays. Consistent with previous results, for both cell
lines, a reduction in the number of migrated and
invaded cells (p < 0.05) was significantly associated
with a decrease in MT1-MMP mRNA and protein
levels, in particular the active form of the MT1-MMP
(Figure 4A, B).
Knockdown of FBI-1 reduced ovarian cancer cell mobility
irrespective of p53 status
As OVCA 420 and SKOV-3 have different p53 status,
it is likely that FBI-1 may affect the cell migration and
invasion in a p53-independent manner. To test this
hypothesis, migration and invasion assays were per-
formed on SKOV-3 cells harboring stable knockdown
Figure 3 Ectopic overexpression of FBI-1 promoted motility, invasiveness and proliferation of ovarian cancer cells. A, In vitro migration
(upper panel) and invasion assays (lower panel) in OVCA 420 (wild-type p53) and SKOV-3 (null p53) cell lines after transfection of pEGFP-FBI-1.
B, mRNA expression of FBI-1, MT1-MMP, MMP-2 and TIMP-2 in cells after transfection of pEGFP-FBI-1 (upper panel). Western blot analysis of the
expression of exogenous GFP-tagged FBI-1 (GFP-FBI-1) and endogenous FBI-1 (Endo-FBI-1) (as detected by anti-FBI-1 antibody) and MT1-MMP in
cells after transfection of pEGFP-FBI-1 (lower panel). C, In vitro migration (upper panel) and invasion (middle panel) assays in OVCA 420 and
SKOV-3 cells transiently transfected with pEGFP-FBI-1, or control vector combined with siRNAs of MT1-MMP or control. Western blot analysis
(lower panel) of the expression of GFP-FBI-1 and Endo-FBI-1, and MT1-MMP in cells expressing FBI-1 transfected with siRNA of MT1-MMP. D, MTT
assays revealed that overexpressed FBI-1 promoted cell growth of OVCA 420 which possessed wild-type p53, but not SKOV-3 cells with mutation
and loss of expression of p53.
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FBI-1 with or without re-induction of wild-type p53. In
both stable shFBI-1 cells with or without re-expression
of wild-type p53, similar decreases in cell invasion and
migration (p < 0.05) were observed, which were again
accompanied by a reduction of MT1-MMP expression
compared with the negative control (NC) (Figure 5A,
B). Together, these results suggested that FBI-1 play an
important role in ovarian cancer cell invasion, migra-
tion, and metastasis, and this function of FBI-1 is
mediated at least in part through its regulation of
MT1-MMP expression but is independent of p53
status.
FBI-1 directly interacts with the promoter of MT1-MMP
and enhanced its expression
The ability of FBI-1 to modulate both MT1-MMP
mRNA and protein levels suggested that FBI-1 may
regulate MT1-MMP expression at transcriptional level.
FBI-1 binding sites have recently been characterized
[18], and three putative FBI-1 consensus sequences
could be identified within ~450bp upstream of the tran-
scription start site of the MT1-MMP gene [24]. A DNA
fragment corresponding to an approximately 600bp of
the 5’-flanking sequence of MT1-MMP was subcloned
upstream of a luciferase reporter assay and used for
gene promoter analysis. Firstly, we investigated whether
FBI-1 would affect MT1-MMP gene transcription activ-
ity in OVCA 420 and SKOV-3 cells after stable FBI-1
knockdown. FBI-1 depletion reduced the MT1-MMP
promoter activity in both cell lines by 3 and 4-fold
when compared with the negative controls, respectively
(Figure 6A). Secondly, the pGL3-Basic-MT1-MMP-Luc
reporter was co-transfected with increasing amounts of
pEGFP-C3-FBI-1 construct. The result showed that FBI-
Figure 4 Stable knockdown of FBI-1 with shRNA reduced motility, invasiveness and proliferation of ovarian cancer cells. A, In vitro
migration (upper panel) and invasion assays (lower panel) in OVCA 420 and SKOV-3 cell lines after stable knockdown of FBI-1. B, mRNA
expression of FBI-1, MT1-MMP, MMP-2 and TIMP-2 in FBI-1 depleted cells (upper panel). Western blot analysis of the expression of FBI-1 (as
detected by anti-FBI-1 antibody) and MT1-MMP in FBI-1 depleted cells (lower panel). C, Concurring with findings shown in Figure 3C, reduction
of cell proliferation following FBI-1 knockdown was found exclusively in OVCA 420 cells with intact p53 function.
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1 efficiently enhanced MT1-MMP promoter activity in a
dose-dependent manner (Figure 6B). Yet, FBI-1 expres-
sion showed no significant effect on MMP-2 promoter
by luciferase reporter assay (data not shown).
In an attempt to further elucidate the induction of
MT1-MMP transcription by FBI-1, a luciferase reporter
construct containing 94bp of the human MT1-MMP
promoter (pGL3-Basic-shortMT-MMP-luc) was applied
for gene promoter analysis. Theoretically, there is no
FBI-1 DNA binding site in this short MT-MMP-luc
sequence [18,24]. Our result showed that overexpression
of FBI-1 could not enhance the transcriptional activity
of this short form of MT1-MMP promoter (data not
shown), further supporting the specificity of the tran-
scription regulatory effect of FBI-1 on MT1-MMP gene.
We next examined whether FBI-1 can bind to the
endogenous MT1-MMP promoter in vivo using the
ChIP assays. Total lysates from parental OVCA 420 and
SKOV-3 cells were used as the input samples and posi-
tive control, while immunoprecipitated lysates without
antibody served as the negative controls. As shown in
Figure 6C, FBI-1 bound directly to the promoter region
of MT1-MMP gene.
FBI-1 promoted ovarian cancer cell proliferation in a p53-
dependent manner
In addition, we also investigated whether FBI-1 could
affect cell proliferation using MTT assay. Introduction
of FBI-1 into OVCA 420 cells with wild-type p53
resulted in an approximately 2-fold enhancement in
cell proliferation (P = 0.003) (Figure 3D). In contrast,
there was no significant effect in SKOV-3 cells which
have no p53 expression. Consistent with these findings,
stable silencing of FBI-1 in OVCA 420 cells led to a
significant decrease in cell proliferation, whereas no
significant changes were observed in SKOV-3 cells
(Figure 4C). The results indicated that the FBI-1 may
modulate ovarian cancer cell proliferation in a p53-
dependent manner.
Discussion
Since ovarian cancer is often asymptomatic until it has
extensive extra-ovarian spread, the high lethality of this
disease is at least partly attributed to the fact that
patients are often at an advanced stage at the time of
first diagnosis [25]. Therefore, a more precise under-
standing of the genetic mechanisms that control cancer
cell dissemination is important. In this report, we estab-
lished for the first time that vast majority of ovarian
cancers produced aberrantly high levels of FBI-1 when
compared with benign or borderline tumors. Overex-
pression of FBI-1 was also observed in most of the ovar-
ian cancer cell lines. Clinicopathological analysis
indicated that high expression of FBI-1 was associated
with advanced stage, shorter overall and disease-free
survival. The cancer cells at metastatic foci and
Figure 5 Introduction of wild type p53 into SKOV-3 cell lines with stable FBI-1 knockdown (shFBI-1) and negative counterpart (NC) led
to A, significant reduction in cell migration and invasion in association with B, reduced expression of FBI-1 (as detected by anti-FBI-1
antibody) and MT1-MMP. Bars, means of migrated or invaded cell numbers ± SD obtained from independent experiments.
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malignant ascites stemmed from advanced diseases
expressed significantly higher levels of FBI-1 when com-
pared with the primary cancers, supporting a role of
FBI-1 in the dissemination of ovarian cancer. Using cell
line models, we further provided evidence supporting
that FBI-1 plays a significant role in migration, invasion,
and proliferation of ovarian cancer.
FBI-1 is encoded by the ZBTB7A gene at chromosome
19p13.3. To date, little is known about the mechanism
leading to FBI-1 up-regulation in cancer. In non -Hodg-
kin B-cell lymphoma, t(14;19)(q32;p13.3) translocation
was reported and aberrant activation of upstream regu-
lators was speculated to be involved in its up-regulation
[26]. Recently, FBI-1 gene amplification was found to be
a frequent event in non-small cell lung cancer [22].
Indeed, a remarkable proportion of our ovarian cancers
(86%) displayed more than two-fold amplification of
ZBTBZA gene and the gene amplification status was sig-
nificantly correlated with its elevated expression at tran-
scriptional level.
Previous reports suggested that the key role of FBI-1
in oncogenesis is to act as a potent inhibitory regulator
of the tumor suppressor gene p14ARF, subsequently lead-
ing to MDM2 constitutive activation and p53 degrada-
tion [18,27]. Taking advantage of ovarian cancer cell
lines with different p53 status, we proved that FBI-1
could enhance cancer cell invasion and migration in a
p53-independent manner. This hypothesis was con-
firmed by wild-type p53 manipulation study. It is likely
that FBI-1 has more target genes than originally antici-
pated. Indeed, studies have suggested that FBI-1 could
repress retinoblastoma gene, another well-known tumor
suppressor gene [20] and could activate fatty-acid
synthase gene (FASN) [28].
Unlike other epithelial carcinomas, which mainly
metastasize through vasculature, “shedding” and “seed-
ing” of ovarian cancer cells from the primary tumor
into peritoneal cavity are also common [29]. These
tumor dissemination processes involve detachment of
tumor cells and degradation of the basement
Figure 6 Dual luciferase assays demonstrated down-regulation of MT1-MMP transcription in A, OVCA 420 and SKOV-3 with stable
shFBI-1 knockdown. Up-regulation of MT1-MMP transcription was found in B, OVCA 420 and SKOV-3 cells after transfection of pEGFP-FBI-1 in a
dose-dependent manner (upper panel); exogenous GFP-tagged FBI-1 (GFP-FBI-1) expression was determined by Western blot analysis using anti-
GFP antibody (lower panel). C, ChIP assays in OVCA 420 and SKOV-3 cell lines. Protein-DNA complexes are immunoprecipitated either with anti-
FBI-1 antibody or negative control, followed by PCR with primers specific to MT1-MMP promoter sequence and agarose-gel electrophoresis for
visualization. Total lysates were used as the input samples and positive control.
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membrane. Thus, proteolytic activity becomes extre-
mely important in ovarian cancer metastasis because it
facilitates the breakthrough and invasion of the
mesothelial monolayer and collagen-rich extracellular
matrix as well. MT1-MMP/MMP-2/TIMP-2 axis is
considered as a central determinant in these processes.
Even though the posttranscriptional regulations of
MT1-MMP have been extensively studied [30,31],
knowledge about its transcriptional regulations remain
limited. The GC-rich promoter of MT1-MMP is dif-
ferent from the other MMPs which are composed of a
conserved TATA box at promoter region [24].
Recently, transcription factors Sp1, Sp3 and Egr-1
have been identified as potent regulators of MT1-
MMP expression in prostate cancer, endothelial and
glomerular mesangial cells [24,32,33]. Our present
findings support that FBI-1 can directly bind to the
promoter of MT1-MMP, but not MMP-2, and induce
MT1-MMP expression in both transcription and pro-
tein levels, in a dose dependent manner leading to cell
migration and invasion. Induction of MT1-MMP tran-
scription by FBI-1 by mutating the potential binding
sites in the MT1-MMP promoter will be performed in
our future study. On the other hand, the findings of
MTT assays on the two ovarian cancer cell lines har-
boring different p53 status suggested that the effect of
FBI-1 on cell proliferation might be restricted in cells
with intact p53 function, consistent with findings from
a previous report [34].
In conclusion, our data showed that FBI-1 promotes
aggressive cancer cell phenotype and its overexpression
is associated with poor clinical outcome. The role of
FBI-1 in ovarian cancer development and progression
also makes it a potential target for therapeutic interven-
tion in ovarian cancer treatment.
Methods
Patient samples and cell lines
220 archival clinical samples (Table 1), including paraf-
fin-embedded tissues of 10 ovarian benign cystadenomas
(ages, 20~77 years; mean age, 32 years), 19 ovarian bor-
derline cystadenomas (ages, 20~46 years; mean age,
30 years), 111 ovarian cancers (ages, 23~78 years; aver-
age age, 50 years) and corresponding metastatic foci in
63 cases, as well as 17 malignant ascites obtained from
stage III/IV ovarian cancer patients, were collected at
the time of surgical resection from 1987 to 2005 at
Department of Pathology, Queen Mary Hospital, the
University of Hong Kong. In addition, 36 paired samples
of ovarian cancers and their corresponding normal fallo-
pian tubes and/or contralateral ovaries were processed
for snap-frozen blocks followed by storage at -80°C and
total RNA and genomic DNA extractions. Both collec-
tion and the use of such patient samples were approved
under the Institutional Ethics Review Board. All diag-
noses have been confirmed by two pathologists using
criteria of the International Federation of Gynecology
Oncology (FIGO).
Culture conditions of two immortalized normal
human ovarian surface epithelium cell lines (HOSE6-3
and HOSE11-12) and 13 ovarian cancer cell lines
(OVCA420, OVCAR-3, SKOV-3, 2780 S, 2780CP, 2008,
2008/C13, SW626, ES2, OC316, DOV13, TOV21G and
TOV112D) were described previously [35-38]. Cell lines
used in the present study were in culture for less than
6 months.
Immunohistochemistry and western blot
Immunohistochemical staining for FBI-1 (1:400; Abcam
Inc, Cambridge, UK; ab36606) was carried out on 220
paraffin-embedded clinical samples with EnVision_Dual
Link System (K4061; Dako, North America, Carpinteria,
CA, USA) [36]. For negative control, primary antibody
was replaced with phosphate buffer saline (PBS).
Sections were assessed for both staining intensity and
percentage, and the final score was determined as
described [35].
For western blot, antibodies specific to FBI-1 (1:600;
Abcam), MT1-MMP (1:1000; Sigma; MS221106), p53
(1:1000; Dako; clone DO-7), and GFP (1:1500; Santa
Cruz; sc-9996) were used to detect the immunoreactivity
according to standard procedures [36]. Our plasmid
expressing FBI-1 was tagged with GFP. GFP is a protein
composed of 238 amino acids (around 31kDa). Endo-
genous FBI-1 (75kDa) and GFP-tagged FBI-1 (106kDa)
could therefore be differentially detected in 7.5% SDS-
PAGE gels using anti-FBI-1 antibody.
RNA and DNA preparation, quantitative
real-time PCR (qPCR)
According to the manufacturer ’s instruction, total
RNA and genomic DNA were isolated from frozen tis-
sues and cell lines by using TRIzol reagent (Invitrogen,
San Diego, CA, USA) or phenol/chloroform (Invitro-
gen) respectively. First-strand cDNA was synthesized
with oligo-dT primer and SuperScript III Reverse
Transcriptase kit (Invitrogen). ABI Prism 7700
Sequence Detection System and SYBR-green PCR mas-
ter mix (Applied Biosystems) were used for qPCR as
described [35].
The primers used for mRNA level evaluation are as fol-
lows: FBI-1, forward, 5’-TCTGCGAGAAGGTCATCC-3’,
and reverse, 5’-CGTAGTTGTGGGCAAAGG-3’ [22]; MT-
MMP, forward, 5’-ACGGAGGTGATCATCATTGAGG-3’
and reverse, 5’-AGATGGGGCTGGACAGACACA-3’
[37,39]; MMP-2, forward, 5’-GGCCCTGTCACTCCTGA-
GAT-3’ and reverse, 5’-GGCATCCAGGTTATG
GGGGA-3’[36,40]; TIMP-2, forward, 5’-GCGGTCAGT
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GAGAAGGAAGTGG-3’, and reverse, 5’-CTTGCACTCG-
CAGCCCATCTG-3’[41]; GAPDH, forward, 5’-TCCA
TGACAACTTTGGTATCGTG-3’ and reverse, 5’-ACAGT
CTTCTGGGTGGCAGTG-3’[35]. Each sample was run in
duplicate and normalized with GAPDH.
FBI-1 gene amplification was also assessed by qPCR
using the following primers: forward, 5’-GAAC-
GAGGGTTTAGTGCA-3’ and reverse, 5’-CGAGCT
GTTCTGGAGAGA-3’ [22]. TRAT1, a single copy gene
in ovarian cancer [42], (forward, 5’-CATGTCAGG-
TAAGTGGCATT-3’; reverse, 5’-GGGTCTTCTCGT
TAGGACTTAG-3’), was served as an internal control.
Each sample was verified in duplicate. Scoring ≥ two-
fold difference in ovarian cancer samples compared with
the corresponding normal counterpart indicated gene
amplification.
Plasmids
The fell-length cDNA of human FBI-1 was amplified
from OVCAR3 cells by PCR using FastStart Taq DNA
polymerase (Roche Applied Science, Indianapolis, USA)
and the primers were forward, 5’- CCCAAGCTTGG-
GATGGCCGGCGGCGTGGACGGC-3’ and reverse,
5’-GCCTTAAGGCTTAGGCGAGTCCGGCTGTGAA-
3’. PCR product was cloned into pEGFP-C3 vector with
Hind III and EcoR I. The integrity and accuracy of
insert was confirmed by sequencing.
pEGFP-C1-p53 construct expressing wild-type p53
and empty vehicle were generous gifts from Dr. Wilson
Ching (Department of Anatomy, The University of
Hong Kong, HKSAR, China). Promoter-luciferase repor-
ter genes, pGL3-Basic-MT1-MMP-Luc (bp -500/+112)
and pGL3-Basic-shortMT-MMP-luc (bp -180/+112)
were kindly provided by Professor Constance E. Brinck-
erhoff [24,43] (Department of Biochemistry and Medi-
cine, Norris Cotton Cancer Center, Dartmouth Medical
School, Lebanon, NH 03756, USA). pGL2-Basic-MMP-
2-Luc (full length of promoter of human MMP-2) was a
generous gift from Dr. Etty N. Benveniste (Department
of Cell Biology, University of Alabama at Birmingham,
Birmingham, Alabama).
Transient transfection and luciferase reporter assay
For ectopic expression of FBI-1 and p53, or knockdown
of MT1-MMP, cells (OCVA 420 and SKOV-3) were
seeded at 90% confluence one day before transient
transfection with various amounts of pEGFP-FBI-1,
pEGFP-p53, siMT1-MMP (Ambion, USA), or controls
using Lipofectamine™2000 (Invitrogen) according to
manufacturer’s instruction. Twenty-four hours after
transfection, cells were collected followed by migration
and invasion assays and proliferation analysis. To assess
the transcriptional activities of MT1-MMP and MMP-2,
1 × 105 cells were grown in 24-well plates and
transiently co-transfected with indicated dosage of
pEGFP-FBI-1 construct and pGL3-Basic-MT1-MMP-
Luc or pGL2-Basic-MMP-2-Luc reporter plasmids. pRL-
SV40-Luc was used as internal control, whereas corre-
sponding empty vectors were served as negative con-
trols. After 48 h incubation, cells were lysed for
luciferase activity analysis using the Dual-Luciferase
Reporter Assay System (Promega, Madison, WI). Renilla
luciferase activities were used to normalize the transfec-
tion efficiency. Each experiment was repeated twice in
duplicate wells.
Establishment of FBI-1 stable knockdown cells
For stable silencing, human FBI-1-specific shRNA (Sure-
Silencing shRNA constructs) and control shRNA vector
(pGeneClip™ puromycin vector) were purchased from
SuperArray (SABioscicences Corporation, Frederick,
USA), transfected into OVCA 420 and SKOV-3 cells,
and selected with puromycin as published previously
[36]. Knockdown efficiency was confirmed by qPCR and
immunoblotting analysis.
In Vitro migration and invasion assays
To determine the impact of FBI-1 on cell mobility, tran-
sient overexpressing or stable knockdown FBI-1 cells
and their control cells were counted and equally plated
on the upper compartments of the 24-wells, 8-μm pore
size Transwell chambers (BD Biosciences, San Jose, CA).
Cell migration and invasion assays were performed with
self-coated Gelatin and Matrigel, respectively. After
24 h, the migrated and invaded cells on the lower sur-
face of membrane were fixed and stained with methanol
mixed crystal violet. All assays were run in indepen-
dently three times.
Proliferation assay
Effect of FBI-1 with or without wild type p53 on cell
proliferation was determined by 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay as
previously described [36]. Every experiment was
repeated twice in triplicate wells, separately.
Chromatin immunoprecipitation (ChIP)
Confluent OVCA 420 and SKOV-3 cells grown on
10-cm dish were cross-linked by adding 1% formalde-
hyde for 10 min. After stopping the reaction with
1.25 M glycine solution and washing with PBS, cells
were suspended in RIPA buffer (150 mM NaCl, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris,
and 5 mM EDTA) containing protease inhibitor cocktail
and sonicated until most of the DNA fragments ranged
from 500 to 1000bp. 50 μl of soluble lysate was saved as
‘input sample’. The rest of the lysate was pre-cleared
with protein A/G beads and salmon sperm DNA. Anti-
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FBI-1 antibody and 30 μl protein A/G beads were then
added to the pre-cleared samples. Samples with no anti-
body incubation were used as negative control. Beads
were centrifuged and washed with RIPA buffer, IP buffer
(0.5 M LiCl, 0.1 M Tris, 1%NP-40, and 1% sodium
deoxycholate), and then RIPA buffer. The bound mate-
rial was eluted from the beads at 85°C for 10 min in
elution buffer (0.1 M NaHCO3 and 1%SDS) and the
RNA and protein was digested using RNase A and pro-
teinase K, respectively. DNA was precipitated and puri-
fied by using phenol/chloroform. The following primers
were used to detect MT1-MMP promoter sequences,
which is designed using Primer3 (v.0.4.0) software based
on the sequence of luciferase reporter construct [24]:
forward, 5’-CCGACAGCGGTCTAGGAAT-3’, reverse,
5’- AGACAACGGGAGGGTCTTG-3’.
Statistical analysis
The clinical-pathological features and the data from in
vitro assays were analyzed using Statistical Package for
Social Science 15.0 for windows (SPSS Inc., Chicago, IL,
USA) software. Spearman’s rho test, Kruskal-Wallis rank
test, Mann-Whitney test, Kaplan-Meier method (using
log-rank test), Cox’s regression model were used to
assess correlation, difference of multiple groups, differ-
ence between two groups of non-parametric data,
survival probability and multivariate survival analysis,
respectively. P value <0.05 was considered to be
significant.
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